# A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

> **NCT05583617** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 200 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Cevostamab
- **DRUG:** Lenalidomide
- **DRUG:** Tocilizumab
- **DRUG:** Iberdomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05583617
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-14
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05583617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05583617, "A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05583617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*